Largest ever edition of CPHI & PMEC India opens at India Expo Mart, over 50,000 participants participate
New Delhi, 28th November 2023: Initiating a groundbreaking expedition to reshape the landscape of pharmaceutical manufacturing, CPHI & PMEC India 2023 commenced today at the India Expo Centre in Greater Noida, Delhi – NCR. Mirroring the trajectory of the flourishing Indian pharma sector, this 16th edition stands as the largest yet, poised to revolutionize the pharmaceutical industry.
It provides an unparalleled platform for stakeholders to participate in extensive dialogues covering pharma machinery, packaging, analytical instruments, laboratory technologies, equipment, ancillaries, ingredients, and beyond.
Igniting collaborative growth across the Pharmaceutical Ecosystem
The 16th edition of CPHI & PMEC India builds on the success of the Pharma Leaders’ Golf and the CPHI Pre-Connect Congress just prior to the show. Themed “Integrate Innovation, Sustainability, and Growth,” this edition aimed to align and shape the roadmap for the next decade of Indian Pharma.
The signature trade expo, South Asia’s largest and most comprehensive pharma congregation, brought together a vast assembly of industry experts, top manufacturers, the buyer’s community, policy advisors, and key stakeholders, uniting suppliers, innovators, and pharmaceutical leaders.
The grand inauguration ceremony was marked by the presence of key dignitaries Dr Veeramani S.V, Vice-Chairman PHARMEXCIL; Mr Harish Jain, President FOPE; Mr Raja Bhanu, Executive Director PHARMEXCIL, Ms Margaret Ma, President & CEO – Informa Markets Asia; Mr Chris Eve, Executive. Vice President – Informa Markets Asia; Mr Adam Anderson, Executive Vice President – Pharma, Informa Markets; Mr Yogesh Mudras, Managing Director, Informa Markets in India; Mr Rahul Deshpande, Senior Group Director, Informa Markets in India, and Mr Ranjith Paul, Group Director, Informa Markets in India.
Highlighting the robust growth of the Indian pharmaceutical industry, Dr. Veeramani S.V., Chairman, Pharmaceuticals Export Promotion Council of India (Pharmexcil), said, “The Indian pharmaceutical industry is on a compelling growth trajectory, evidenced by an 8% year-to-date increase in exports and a remarkable 29% surge in October alone. This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the US and Europe. Despite challenges in CIS countries, the global reception of Indian pharmaceuticals remains positive. The domestic market has exhibited impressive growth, exceeding 10%. Driven by this momentum, I am confident in reaching the 130 billion mark by 2030, advocating for a consistent 10% growth in both domestic and export markets. Expos like CPHI & PMEC India are instrumental in propelling our industry forward, fostering innovation, and reinforcing India’s position on the global pharmaceutical stage.”
Sharing insights on the forward-looking stance Mr Anil Matai, Director General, Pharmaceuticals Export Promotion Council of India (OPPI) said, “While discussions revolve around India’s pharmaceutical landscape in 2030, our industry is visionary, setting its sights on India in 2047. Aligned with Prime Minister Narendra Modi’s concept of Amrit Kal, we anticipate a trajectory of sustained growth. Exceeding the projected $130 billion mark, the Department of Pharmaceuticals (DOP) envisions an ambitious $200 billion goal. Achieving this necessitates regulatory reforms to foster industry growth, address patient needs, and promote disruptive innovation, as we learned from the pandemic. Regarding the pharmaceutical sector’s outlook, we foresee stable double-digit growth, around 13-14%, conditional on consistent policies that streamline doing business. CPHI serves as a crucial platform to deliberate on achievements, challenges, and influence regulators for favourable business conditions.”
